# A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

> **NCT01395927** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rifampin
- **DRUG:** Canagliflozin

## Key facts

- **NCT ID:** NCT01395927
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2013-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395927, "A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01395927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*